Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)

BACKGROUND: Systematic data are lacking on the immune response toward SARS-CoV-2 mRNA vaccination in SPMS patients on disease-modifying therapies (DMTs). OBJECTIVE: The AMA-VACC clinical trial was designed to characterize immune responses to SARS-CoV-2 mRNA vaccines in siponimod-treated SPMS patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Groth, Marie, Rauser, Benedict, Bopp, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647234/
https://www.ncbi.nlm.nih.gov/pubmed/36381503
http://dx.doi.org/10.1177/17562864221135305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647234/
https://www.ncbi.nlm.nih.gov/pubmed/36381503
http://dx.doi.org/10.1177/17562864221135305

Ejemplares similares